CYTOKINETICS INC

NASDAQ: CYTK (Cytokinetics, Incorporated)

Last update: 16 hours ago

41.62

-0.56 (-1.33%)

Previous Close 42.18
Open 43.00
Volume 1,556,516
Avg. Volume (3M) 1,331,496
Market Cap 4,911,742,464
Price / Sales 1.39
Price / Book 60.31
52 Weeks Range
40.53 (-2%) — 81.36 (95%)
Earnings Date 25 Feb 2025 - 3 Mar 2025
Operating Margin (TTM) -30,410.58%
Diluted EPS (TTM) -5.38
Quarterly Revenue Growth (YOY) 22.50%
Total Debt/Equity (MRQ) 727.94%
Current Ratio (MRQ) 9.28
Operating Cash Flow (TTM) -404.36 M
Levered Free Cash Flow (TTM) -242.42 M
Return on Assets (TTM) -30.13%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Mixed
Biotechnology (Global) Mixed Mixed
Stock Cytokinetics, Incorporated Bearish Bearish

AIStockmoo Score

0.9
Analyst Consensus 4.0
Insider Activity -1.5
Price Volatility 4.5
Technical Moving Averages 0.0
Technical Oscillators -2.5
Average 0.90

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
CYTK 5 B - - 60.31
SRRK 4 B - - 42.81
ARWR 3 B - - 13.41
SPRY 1 B - - 6.19
GHRS 868 M - - 4.94
SANA 728 M - - 2.41

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Sector Healthcare
Industry Biotechnology
Investment Style Small Value
% Held by Insiders 0.54%
% Held by Institutions 120.05%
52 Weeks Range
40.53 (-2%) — 81.36 (95%)
Price Target Range
67.00 (60%) — 120.00 (188%)
High 120.00 (HC Wainwright & Co., 188.32%) Buy
Median 81.00 (94.62%)
Low 67.00 (Morgan Stanley, 60.98%) Buy
Average 86.00 (106.63%)
Total 8 Buy
Avg. Price @ Call 45.12
Firm Date Target Price Call Price @ Call
Morgan Stanley 13 Feb 2025 67.00 (60.98%) Buy 41.62
Citigroup 07 Feb 2025 86.00 (106.63%) Buy 42.76
JMP Securities 07 Feb 2025 78.00 (87.41%) Buy 42.76
14 Jan 2025 78.00 (87.41%) Buy 45.23
Needham 06 Feb 2025 72.00 (72.99%) Buy 46.17
02 Dec 2024 72.00 (72.99%) Buy 50.63
HC Wainwright & Co. 22 Jan 2025 120.00 (188.32%) Buy 46.82
21 Jan 2025 120.00 (188.32%) Buy 45.82
Stifel 22 Jan 2025 80.00 (92.22%) Buy 46.82
RBC Capital 18 Dec 2024 82.00 (97.02%) Buy 46.36
Mizuho 21 Nov 2024 103.00 (147.48%) Buy 47.67
Show more
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
MALIK FADY IBRAHAM - 49.20 -2,000 -98,400
Aggregate Net Quantity -2,000
Aggregate Net Value ($) -98,400
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 49.20
Name Holder Date Type Quantity Price Value ($)
MALIK FADY IBRAHAM Officer 04 Feb 2025 Sell (-) 2,000 49.20 98,400
MALIK FADY IBRAHAM Officer 04 Feb 2025 Option execute 2,000 - -
Date Type Details
13 Feb 2025 Announcement Cytokinetics to Announce Fourth Quarter Results on February 27, 2025
11 Feb 2025 Announcement Cytokinetics Names Robert E. Landry to Board of Directors
05 Feb 2025 Announcement Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
04 Feb 2025 Announcement Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 Jan 2025 Announcement Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program
21 Jan 2025 Announcement Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction
13 Jan 2025 Announcement Cytokinetics Announces 2025 Corporate Milestones and Vision 2030
06 Jan 2025 Announcement Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
03 Jan 2025 Announcement Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
23 Dec 2024 Announcement Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
20 Dec 2024 Announcement Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
03 Dec 2024 Announcement Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction
03 Dec 2024 Announcement Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Dec 2024 Announcement Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
02 Dec 2024 Announcement Cytokinetics to Participate in December Investor Conferences
19 Nov 2024 Announcement Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan
16 Nov 2024 Announcement Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024
16 Nov 2024 Announcement Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria